BioCryst Pharmaceuticals : First Quarter 2021 Conference Call
May 06, 2021 at 04:41 pm EDT
Share
First Quarter 2021 Results Call
Corporate Update & Financial Results
May 6, 2021
Forward-Looking Statements
BioCryst's presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward- looking statements. For additional information, including important risk factors, please refer to BioCryst's documents filed with the SEC and located at https://ir.biocryst.com/financial-information/sec-filings.
.
2
Agenda
Corporate Update:
Jon Stonehouse - President and Chief Executive Officer
Global ORLADEYO™ (berotralstat) Launches:
Charlie Gayer - Chief Commercial Officer
Megan Sniecinski - Chief Business Officer
BCX9930 Update
Dr. Bill Sheridan - Chief Medical Officer
Financial Update
Anthony Doyle - Chief Financial Officer
Summary and Q&A
3
Significant Milestones in 2021
Q12021
Approval decision
on ORLADEYO in Japan (January 2021)
Data from completed BCX9930 dose ranging study in PNH (R&D Day: March 22)
Q22021
Approval decision
on ORLADEYO in EU
Revenues reported from Q1/first full quarter of ORLADEYO sales in US
Launch of ORLADEYO in Japan
Launch of ORLADEYO in Germany
Q32021Q42021
BCX9930 Advanced Development Trials
BCX9250 Next Steps
ORLADEYO REVENUES
4
Cash position (in millions)
Cash, cash equivalents, restricted cash & investments at December 31, 2020
$303
Cash, cash equivalents, restricted cash & investments at March 31, 2021
$244
Senior credit facility A
$125
A - From Athyrium Capital Management, $125M interest-only for 5-year term
In the launch period for ORLADEYO, the company is not providing specific revenue or operating expense
guidance. Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023.
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
BioCryst Pharmaceuticals Inc. published this content on 06 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2021 20:40:07 UTC.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
BIOCRYST PHARMACEUTICALS, INC. 
